LOWER PREVALENCE OF ANTI-HEPATITIS-C ANTIBODY IN DIALYSIS AND RENAL-TRANSPLANT PATIENTS IN IRELAND

被引：12

作者：

CONLON, PJ ^{[1
]}

WALSHE, JJ ^{[1
]}

SMYTH, EG ^{[1
]}

MCNAMARA, EB ^{[1
]}

DONOHOE, J ^{[1
]}

CARMODY, M ^{[1
]}

机构：

[1] BEAUMONT HOSP,DEPT NEPHROL,POB 1297,BEAUMONT RD,DUBLIN 9,IRELAND

来源：

IRISH JOURNAL OF MEDICAL SCIENCE | 1993年 / 162卷 / 04期

关键词：

D O I：

10.1007/BF02942105

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

It is well recognised that haemodialysis and renal transplant patients are at increased risk of developing non-A, non-B hepatitis. Recently the genome of hepatitis C virus (HCV), the major causative agent for non-A, non-B hepatitis, has been isolated. Anti-HCV seroprevalence was assessed in all haemodialysis patients (266) in Ireland who in March 1990 had been dialysed for at least 6 months. For comparative purposes, 272 patients who had functioning renal transplants for greater than 6 months were also studied. Potential risk factors such as age, number of blood transfusions and time on dialysis were evaluated. The prevalence of HCV infection as evidenced by antibody detection was only 1.1% for transplant and 1.7% for haemodialysis patients. This compares to a reported incidence of between 10% and 50% found elsewhere. Two of the 5 anti-HCV positive haemodialysis patients and 2 of the 3 transplant patients had biochemical evidence of liver disease. From stored sera it was possible to ascertain when patients acquired HCV. Whether the very low prevalence of anti-HCV in Irish patients is due to the low prevalence of the virus in the general population, the policy of non reimbursement of blood donors, genetic or other factors, remains to be determined.

引用

页码：145 / 147

页数：3

共 24 条

[1]

Nielson V., Clausen E., Ranek L., Liver impairment during chronic haemodialysis and after renal transplantation, Acta Med Scand., 197, pp. 229-234, (1975)

[2]

Weir M.R., Kirkmann R.L., Strom T.B., Tilney N.L., Et al., Liver disease in recipients in of long-functioning renal allografts, Kidney International, 28, pp. 839-844, (1985)

[3]

Huang C.C., Lai M.K., Fong M.I., Hepatitis B liver disease in cyclosporine-treated renal allograft recipients, Transplantation, 49, pp. 540-544, (1990)

[4]

Feinstone S., Kapikan A., Purcell R., Alter H., Et al., Tranfusion- associated hepatitis not due to viral hepatitis type A or B, The New England Journal of Medicine, 292, pp. 767-770, (1975)

[5]

Rakela J., Redker A.G., Chronic liver disease after acute non-A, non-B viral hepatitis, Gastroenterology, 77, (1979)

[6]

Berman M., Alter H.J., Ishak G., Purcell R.H., The chronic sequelae of non-A, non-B hepatitis, Annals of Internal Medicine, 91, pp. 1-6, (1979)

[7]

Koretz R., Stone O., Gitnick G., The long-term course of non-A, non-B post-transfusion hepatitis, Gastroenterology, 79, pp. 893-898, (1980)

[8]

Knodell R., Conrad M., Ishak K., Development of chronic liver disease after acute non-A,non-B post transfusion hepatitis, Gastroenterology, 72, pp. 902-909, (1977)

[9]

Choo Q.L., Kuo G., Weiner A.J., Overby L.R., Et al., Isolation of a cDN A clone derived from a blood borne non-A, non-B viral hepatitis genome, Science, 244, pp. 359-361, (1989)

[10]

Kuo G., Alter C., Gitnick G.L., Redeker A-G., Et al., Anassay for circulating antibodies to a major etiologic virus of human non- A, non-B hepatitis, Science, 244, pp. 362-364, (1989)

← 1 2 3 →